USE OF AMINOGLUTETHIMIDE AS 2ND-LINE ENDOCRINE THERAPY IN METASTATIC BREAST-CANCER

被引：0

作者：

KAYE, SB ^{[1
]}

WOODS, RL ^{[1
]}

FOX, RM ^{[1
]}

COATES, AS ^{[1
]}

TATTERSALL, MHN ^{[1
]}

机构：

[1] UNIV SYDNEY,LUDWIG INST CANC RES,SYDNEY,NSW 2006,AUSTRALIA

来源：

CANCER RESEARCH | 1982年 / 42卷 / 08期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：3445 / 3447

页数：3

共 50 条

[1] AMINOGLUTETHIMIDE AS 2ND-LINE ENDOCRINE TREATMENT IN METASTATIC BREAST-CANCER
PRONZATO, P
ARDIZZONI, A
LIONETTO, R
CONTE, P
ROSSO, R
TUMORI, 1985, 71 (03) : 297 - 300
[2] AMINOGLUTETHIMIDE AS 2ND LINE ENDOCRINE THERAPY IN ADVANCED BREAST-CANCER
BRUFMAN, G
BIRAN, S
ANTICANCER RESEARCH, 1986, 6 (05) : 1065 - 1068
[3] AMINOGLUTETHIMIDE AS 2ND-LINE HORMONAL-THERAPY IN ADVANCED BREAST-CANCER - RESPONSE AND TOXICITY
ROWELL, NP
GILMORE, OJA
PLOWMAN, PN
HUMAN TOXICOLOGY, 1987, 6 (03): : 227 - 232
[4] 2ND LINE HORMONAL-THERAPY WITH AMINOGLUTETHIMIDE IN METASTATIC BREAST-CANCER
BRUFMAN, G
BIRAN, S
ACTA ONCOLOGICA, 1990, 29 (06) : 717 - 720
[5] MITOXANTRONE AS 2ND-LINE SINGLE AGENT IN METASTATIC BREAST-CANCER
STEIN, M
BOROVIK, R
ROBINSON, E
ONCOLOGY, 1991, 48 (04) : 265 - 269
[6] EFFECTIVENESS AND UTILITY OF A 2ND-LINE TREATMENT IN METASTATIC BREAST-CANCER
PORZSOLT, F
MAYERSTEINACKER, R
EGGL, C
ONKOLOGIE, 1995, 18 (01): : 48 - 52
[7] IMPACT OF 2ND-LINE THERAPIES ON SURVIVAL IN METASTATIC BREAST-CANCER
FRYE, D
HORTOBAGYI, GN
BUZDAR, AU
BREAST CANCER RESEARCH AND TREATMENT, 1988, 12 (01) : 124 - 124
[8] AMINOGLUTETHIMIDE AS 2ND LINE THERAPY IN ADVANCED BREAST-CANCER
ELOMAA, I
BLOMQVIST, C
RISSANEN, P
BREAST CANCER RESEARCH AND TREATMENT, 1986, 7 : 51 - 54
[9] 2ND-LINE CHEMOTHERAPY WITH MITOXANTRONE AS A SINGLE AGENT IN METASTATIC BREAST-CANCER
BRUFMAN, G
HAIM, N
BENBARUCH, N
SULKES, A
JOURNAL OF CHEMOTHERAPY, 1993, 5 (01) : 43 - 46
[10] INTRAVENOUS VINORELBINE AS FIRST-LINE AND 2ND-LINE THERAPY IN ADVANCED BREAST-CANCER
WEBER, BL
VOGEL, C
JONES, S
HARVEY, H
HUTCHINS, L
BIGLEY, J
HOHNEKER, J
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (11) : 2722 - 2730

← 1 2 3 4 5 →